Clinical trial NCT04306939: Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Official title: Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Chronic Pancreatitis
Inflammatory Bowel Diseases
Hepatitis
NASH - Nonalcoholic Steatohepatitis
Acute Pancreatitis
Rheumatoid Arthritis
Diabetes Mellitus
Dyslipidemias
Multiple Sclerosis
Irritable Bowel Syndrome
Chronic Pain
Chronic Disease
Chronic Kidney Diseases
Crohn Disease
Celiac Disease
Biliary Cirrhosis
Bile Acid Synthesis Defect
Gastritis
Cholecystitis
Cholelithiases
IPMN
Cyst Pancreas
Cystic Fibrosis
Pancreatic Exocrine Insufficiency
Diarrhea Chronic
Constipation - Functional
Constipation Chronic Idiopathic
Keywords: fibrosis
chronic inflammation
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2020-03-13
Enrollment: 120000
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen in a UPMC facility with available electronic health records

Brief summary: This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect clinical decision making.

The study will evaluate risk factors and co-variants, including genetic variants that are associated with disease progression such as pain, inflammation, organ dysfunction, disability and quality of life.

Detailed description: The Genomic Resource to Enhance Available Therapies (GREAT1.0) Study is a research program for personalized medicine. It is a highly annotated genetic and biosample resource for multiple nested observational cohort studies. It is designed to begin to understand the mechanisms underlying complex diseases using clinical information from the UPMC electronic health record (EHR), from case-report forms, and from biological samples.

Aim 1. To test the hypothesis that point-of-care electronic health record (EHR)-based phenotyping and clinical measures will be useful for classifying patient by disease risk, subtype, activity, complications, quality of life or using statistical or systems approaches.

Aim 2. To test the hypothesis that common diseases can be subtyped using genotype data.

Aim 3. To test the hypothesis biological samples will provide additional functional and mechanistic information about subject health, disease or state.

The study will be conducted using UPMC patients and population controls. Consent will allow EHR and/or case report form data, plus biological samples to be given a unique code number and transferred to researchers for analysis. Consent will also allow for a secure link to be maintained allowing the research data or samples to be updated, and to contact the clinical team and/or subject to provide them with additional information.

Eligibility criteria: Inclusion Criteria:

Case Subjects

* Clinical diagnosis of a chronic disease or disorder (ex. pancreatitis, hepatitis or fatty liver, inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, chronic pain syndromes, diabetes, hypertension, cardiovascular disease, chronic kidney disease, chronic neurologic disorders, rheumatological disorders, endocrine disorders, chronic pulmonary diseases, sinorespiratory disorders, chronic skin diseases, cancers and related disorders)
* Ability to read and write in English;
* Ability to provide informed consent

Control Subjects

• UPMC patients age 12 years without a chronic disorder.

Exclusion Criteria:

* Chronic infectious disease as the primary medical problem
* Less than 12 years of age
* Inability of the subject to understand the protocol
* Inability to the subject provide informed consent

Primary outcomes:
measure: Define the molecular disorders contributing to clinicopathological disease definitions for common complex disorders
timeFrame: through study completion, an average of 1 year
measure: Define risk factors for disease progression, severity, complications and poor quality of life.
timeFrame: through study completion, an average of 1 year
measure: Common disease mechanisms and repurposing of medications.
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Pain profile
timeFrame: through study completion, an average of 1 year
measure: Patient Reported Global Health Assessment
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: David C Whitcomb, MD, PhD
role: STUDY_CHAIR
References:
citation: Whitcomb DC. Primer on Precision Medicine for Complex Chronic Disorders. Clin Transl Gastroenterol. 2019 Jul;10(7):e00067. doi: 10.14309/ctg.0000000000000067.